Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues.

Walters DC, Arning E, Bottiglieri T, Jansen EEW, Salomons GS, Brown MN, Schmidt MA, Ainslie GR, Roullet JB, Gibson KM.

Neurochem Int. 2019 May;125:151-162. doi: 10.1016/j.neuint.2019.02.015. Epub 2019 Feb 26.

PMID:
30822440
2.

Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Walters DC, Jansen EEW, Ainslie GR, Salomons GS, Brown MN, Schmidt MA, Roullet JB, Gibson KM.

Pharmacol Res Perspect. 2019 Jan 7;7(1):e00456. doi: 10.1002/prp2.456. eCollection 2019 Feb.

3.

Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies.

Vogel KR, Ainslie GR, Walters DC, McConnell A, Dhamne SC, Rotenberg A, Roullet JB, Gibson KM.

J Inherit Metab Dis. 2018 Jul;41(4):699-708. doi: 10.1007/s10545-018-0153-8. Epub 2018 Feb 19.

4.

In vitro modeling of experimental succinic semialdehyde dehydrogenase deficiency (SSADHD) using brain-derived neural stem cells.

Vogel KR, Ainslie GR, Jansen EE, Salomons GS, Roullet JB, Gibson KM.

PLoS One. 2017 Oct 20;12(10):e0186919. doi: 10.1371/journal.pone.0186919. eCollection 2017.

5.

Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder.

Vogel KR, Ainslie GR, McConnell A, Roullet JB, Gibson KM.

Toxicol In Vitro. 2018 Feb;46:203-212. doi: 10.1016/j.tiv.2017.10.015. Epub 2017 Oct 12.

6.

Targeted screening of succinic semialdehyde dehydrogenase deficiency (SSADHD) employing an enzymatic assay for γ-hydroxybutyric acid (GHB) in biofluids.

Wernli C, Finochiaro S, Volken C, Andresen-Streichert H, Buettler A, Gygax D, Salomons GS, Jansen EE, Ainslie GR, Vogel KR, Gibson KM.

Mol Genet Metab Rep. 2016 Aug 17;11:81-89. doi: 10.1016/j.ymgmr.2016.07.009. eCollection 2017 Jun.

7.

Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies.

Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF.

Clin Transl Sci. 2017 Sep;10(5):380-386. doi: 10.1111/cts.12473. Epub 2017 May 23.

8.

Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency.

Johansen SS, Wang X, Sejer Pedersen D, Pearl PL, Roullet JB, Ainslie GR, Vogel KR, Gibson KM.

JIMD Rep. 2017;36:93-98. doi: 10.1007/8904_2017_3. Epub 2017 Feb 18.

9.

In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding.

Vogel KR, Ainslie GR, Roullet JB, McConnell A, Gibson KM.

Toxicol In Vitro. 2017 Apr;40:196-202. doi: 10.1016/j.tiv.2017.01.013. Epub 2017 Jan 22.

PMID:
28119166
11.

Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity?

Vogel KR, Ainslie GR, Pearl PL, Gibson KM.

Clin Pharmacol Ther. 2017 Apr;101(4):458-461. doi: 10.1002/cpt.581. Epub 2017 Feb 7.

12.

mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.

Vogel KR, Ainslie GR, Schmidt MA, Wisor JP, Gibson KM.

Pediatr Neurol. 2017 Jan;66:44-52.e1. doi: 10.1016/j.pediatrneurol.2016.09.016. Epub 2016 Oct 3.

13.

Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Vogel KR, Ainslie GR, Jansen EE, Salomons GS, Gibson KM.

Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):33-42. doi: 10.1016/j.bbadis.2016.10.009. Epub 2016 Oct 17.

15.

Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Malaspina P, Roullet JB, Pearl PL, Ainslie GR, Vogel KR, Gibson KM.

Neurochem Int. 2016 Oct;99:72-84. doi: 10.1016/j.neuint.2016.06.009. Epub 2016 Jun 14. Review.

16.

Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse.

Vogel KR, Ainslie GR, Jansen EE, Salomons GS, Gibson KM.

Ann Clin Transl Neurol. 2015 Jun;2(6):699-706. doi: 10.1002/acn3.200. Epub 2015 Apr 17.

17.

Physiological Competition of Brain Phenylalanine Accretion: Initial Pharmacokinetic Analyses of Aminoisobutyric and Methylaminoisobutyric Acids in Pahenu2-/- Mice.

Vogel KR, Ainslie GR, Phillips B, Arning E, Bottiglieri T, Shen DD, Gibson KM.

Mol Genet Metab Rep. 2015 Jun 1;3:80-87.

18.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15.

19.

Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.

Ainslie GR, Wolf KK, Li Y, Connolly EA, Scarlett YV, Hull JH, Paine MF.

J Pharmacol Exp Ther. 2014 Dec;351(3):576-84. doi: 10.1124/jpet.114.216838. Epub 2014 Sep 24.

20.

Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity.

VanderMolen KM, Ainslie GR, Paine MF, Oberlies NH.

J Pharm Biomed Anal. 2014 Sep;98:260-5. doi: 10.1016/j.jpba.2014.05.038. Epub 2014 Jun 2.

21.

Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis.

Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, Yamate J, Kosyk O, Shymonyak S, Bradford BU, Boorman GA, Bataller R, Rusyn I.

Toxicol Sci. 2013 Mar;132(1):53-63. doi: 10.1093/toxsci/kfs342. Epub 2013 Jan 3.

22.

Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug.

Generaux CN, Ainslie GR, Bridges AS, Ismail MA, Boykin DW, Tidwell RR, Thakker DR, Paine MF.

Drug Metab Dispos. 2013 Feb;41(2):518-28. doi: 10.1124/dmd.112.048231. Epub 2012 Dec 6.

PMID:
23223498
23.

Forms of a self associating autoantibody complex between a monoclonal human IgG1 and human serum albumin.

Jentoft JE, Bolinger L, Ainslie GR, Tandler B.

Mol Immunol. 1987 Feb;24(2):163-9.

PMID:
3614209
24.

The effect of oligomeric environment on the kinetics of lactate dehydrogenase subunits.

Ainslie GR Jr, Cleland WW.

Arch Biochem Biophys. 1982 Jun;216(1):101-4. No abstract available.

PMID:
7103501
25.

Hysteretic enzymes.

Neet KE, Ainslie GR Jr.

Methods Enzymol. 1980;64:192-226. No abstract available.

PMID:
7374453
26.

Cooperativity and the slow isomerization of deta-chymotrypsin.

Ainslie GR Jr, Neet KE.

Mol Cell Biochem. 1979 Apr 2;24(3):183-91. No abstract available.

PMID:
37427
27.

Bimodal substrate inhibition of lactate dehydrogenase. Factors affecting the enzyme in vivo.

Burgner JW 2nd, Ainslie GR Jr, Cleland WW, Ray WJ Jr.

Biochemistry. 1978 May 2;17(9):1646-53. No abstract available.

PMID:
207313
28.

Conformational changes and association of chemically modified chymotrypsins.

Neet KE, Sackrison KM, Ainslie GR, Barritt LC.

Arch Biochem Biophys. 1974 Feb;160(2):569-76. No abstract available.

PMID:
4831628
29.

Transients and cooperativity. A slow transition model for relating transients and cooperative kinetics of enzymes.

Ainslie GR Jr, Shill JP, Neet KE.

J Biol Chem. 1972 Nov 10;247(21):7088-96. No abstract available.

30.

Isotope exchange studies on liver alcohol dehydrogenase with cyclohexanol and cyclohexanone as reactants.

Ainslie GR Jr, Cleland WW.

J Biol Chem. 1972 Feb 10;247(3):946-51. No abstract available.

Supplemental Content

Loading ...
Support Center